Literature DB >> 2208131

Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model.

G D Steinberg1, C B Brendler, T Ichikawa, R A Squire, J T Isaacs.   

Abstract

Cohorts of 4- to 5-wk-old female Fischer 344 rats received four biweekly 1.5-mg doses of N-methyl-N-nitrosourea (MNU) intravesically and were sacrificed at various intervals. By 13 wk after initiation of the carcinogen, all animals have flat epithelial atypia and/or papillary transitional cell bladder carcinomas, and 67% of the lesions are histological Grade II or III. By 20 wk, 83% have gross bladder wall muscle-invasive tumors that eventually kill the host. There was no gross evidence of visceral metastases in any animal. This rat model of transitional cell carcinoma of the bladder is useful because: (a) all animals develop progressive neoplastic changes in situ within 4 mo after initiation of MNU treatment; (b) these lesions progress to grossly detectable bladder tumors which invade the bladder wall and kill the host; (c) this full progression of bladder epithelial cells from atypical hyperplasia through flat carcinoma in situ to transitional cell carcinoma occurs at discrete time points; (d) the histology of the grossly detectable tumors is that of invasive transitional cell carcinomas; and (e) no leukemias, breast cancers, lymphomas, or other non-bladder tumors are induced. Six MNU-induced bladder wall-invasive tumors were karyotyped, and all tumors were diploid with 42 chromosomes. Three of the tumors had apparently normal karyotypes, while three tumors had karyotypes containing one or more cytogenetic structural markers. One of these markers (i.e., 8p+) was observed in two of the three tumors. The level of expression of total ras p21 (N-, Ki-, and Ha-ras p21) and codon 12-mutated c-Ha-ras p21 (i.e., glycine to glutamic acid mutation in codon 12) in a series of these MNU-induced bladder tumors was determined by Western blot analysis. No increase in the total ras p21 nor any expression of codon 12-mutated c-Ha-ras p21 was detected in any of these tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208131

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Experimental animal model and RNA interference: a promising association for bladder cancer research.

Authors:  Leonardo Oliveira Reis; Tiago Campos Pereira; Wagner José Favaro; Valéria Helena Alves Cagnon; Iscia Lopes-Cendes; Ubirajara Ferreira
Journal:  World J Urol       Date:  2009-02-13       Impact factor: 4.226

2.  Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Authors:  Max Kates; Abhijit Date; Takahiro Yoshida; Umara Afzal; Pranjali Kanvinde; Taarika Babu; Nikolai A Sopko; Hotaka Matsui; Noah M Hahn; David J McConkey; Alexander Baras; Justin Hanes; Laura Ensign; Trinity J Bivalacqua
Journal:  Clin Cancer Res       Date:  2017-08-14       Impact factor: 12.531

3.  Dr. Coffey's visionary contributions to urological research in China and Japan.

Authors:  Jun Shimazaki; Leland Wk Chung; Haiyen E Zhau; Tomohiko Ichikawa
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

4.  Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Authors:  Peter A Raven; Ninadh M D'Costa; Igor Moskalev; Zheng Tan; Sebastian Frees; Claudia Chavez-Munoz; Alan I So
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

5.  Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Authors:  Max Kates; Thomas Nirschl; Nikolai A Sopko; Hotaka Matsui; Christina M Kochel; Leonardo O Reis; George J Netto; Mohammad Hoque; Noah M Hahn; David J McConkey; Alex S Baras; Charles G Drake; Trinity J Bivalacqua
Journal:  Cancer Immunol Res       Date:  2017-06-06       Impact factor: 11.151

6.  Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer.

Authors:  Trinity J Bivalacqua; Laura M Ensign; Abhijit A Date; Max Kates; Takahiro Yoshida; Taarika Babu; Umara Afzal; Pranjali Kanvinde; Alexander Baras; Nicole Anders; Ping He; Michelle Rudek; Justin Hanes
Journal:  Drug Deliv Transl Res       Date:  2020-11-08       Impact factor: 4.617

7.  Bracken fern-induced bladder tumors in guinea pigs. A model for human neoplasia.

Authors:  P P Bringuier; E Piaton; N Berger; F Debruyne; P Perrin; J Schalken; M Devonec
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

8.  The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma.

Authors:  R J van Moorselaar; T Ichikawa; H E Schaafsma; P H Jap; J T Isaacs; P van Stratum; F C Ramaekers; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1993

9.  Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy.

Authors:  P J Russell; I Ho Shon; G R Boniface; M E Izard; J Philips; D Raghavan; K Z Walker
Journal:  Urol Res       Date:  1991

10.  Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer.

Authors:  Wagner J Fávaro; Odilon S Nunes; Fabio Rf Seiva; Iseu S Nunes; Lisa K Woolhiser; Nelson Durán; Anne J Lenaerts
Journal:  Infect Agent Cancer       Date:  2012-06-18       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.